Global Next Generation Cancer Diagnostics Market

Next Generation Cancer Diagnostics Market Size, Share, Growth Analysis, By Technology(Next-generation Sequencing, qPCR & Multiplexing, Lab-on-a-chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays), By Application(Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis), By Cancer Type(Lung, Breast, Colorectal, Cervical), By Function(Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35A2226 | Region: Global | Published Date: September, 2024
Pages: 219 | Tables: 67 | Figures: 77

Next Generation Cancer Diagnostics Market Competitive Landscape

These companies are involved in the development, manufacturing, and commercialization of a range of next-generation cancer diagnostic technologies and tests, including liquid biopsies, NGS, and imaging techniques. The market is characterized by intense competition, with companies competing on the basis of product features, quality, pricing, and customer service.

Top Player’s Company Profiles in Next Generation Cancer Diagnostics Market

  • Abbott Laboratories (US) 
  • Agilent Technologies, Inc. (US) 
  • Bio-Rad Laboratories, Inc. (US) 
  • Danaher Corporation (US) 
  • Exact Sciences Corporation (US) 
  • F. Hoffmann-La Roche Ltd. (Switzerland) 
  • GE Healthcare (US) 
  • Guardant Health, Inc. (US) 
  • Hologic, Inc. (US) 
  • Illumina, Inc. (US) 
  • Merck & Co., Inc. (US) 
  • Myriad Genetics, Inc. (US) 
  • NanoString Technologies, Inc. (US) 
  • Natera, Inc. (US) 
  • NeoGenomics, Inc. (US) 
  • Qiagen N.V. (Netherlands) 
  • Quest Diagnostics Incorporated (US) 
  • Siemens Healthineers AG (Germany) 
  • Sysmex Corporation (Japan) 
  • Thermo Fisher Scientific, Inc. (US) 
  • Veracyte, Inc. (US)

Next Generation Cancer Diagnostics Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Next Generation Cancer Diagnostics Market size was valued at USD 11.60 Billion in 2022 and is poised to grow from USD 13.66 Billion in 2023 to USD 43.02 Billion by 2031, at a CAGR of 17.8% during the forecast period (2024-2031).

These companies are involved in the development, manufacturing, and commercialization of a range of next-generation cancer diagnostic technologies and tests, including liquid biopsies, NGS, and imaging techniques. The market is characterized by intense competition, with companies competing on the basis of product features, quality, pricing, and customer service. 'Abbott Laboratories (US) ', 'Agilent Technologies, Inc. (US) ', 'Bio-Rad Laboratories, Inc. (US) ', 'Danaher Corporation (US) ', 'Exact Sciences Corporation (US) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'GE Healthcare (US) ', 'Guardant Health, Inc. (US) ', 'Hologic, Inc. (US) ', 'Illumina, Inc. (US) ', 'Merck & Co., Inc. (US) ', 'Myriad Genetics, Inc. (US) ', 'NanoString Technologies, Inc. (US) ', 'Natera, Inc. (US) ', 'NeoGenomics, Inc. (US) ', 'Qiagen N.V. (Netherlands) ', 'Quest Diagnostics Incorporated (US) ', 'Siemens Healthineers AG (Germany) ', 'Sysmex Corporation (Japan) ', 'Thermo Fisher Scientific, Inc. (US) ', 'Veracyte, Inc. (US)'

The rising demand for personalized medicines is another factor driving the growth of the next generation cancer diagnostics market. Personalized medicine involves tailoring treatments to individual patients based on their genetic profile and other characteristics. Next generation cancer diagnostics tools can help identify patients who are most likely to benefit from personalized treatments.

Liquid biopsy tests have emerged as a promising alternative to traditional tissue biopsy tests for cancer diagnosis and treatment monitoring. These tests involve the analysis of a patient's blood, urine, or other bodily fluids to detect cancer cells and other biomarkers. Liquid biopsy tests are less invasive and less expensive than traditional biopsy tests, and they can provide more frequent and accurate results. As a result, there has been a growing adoption of liquid biopsy tests in the market, with several companies investing in the development of these tests.

The largest market is expected to be in North America in 2023 and for the duration of the forecast. High per capita healthcare spending and supportive healthcare policies are responsible for the regional market expansion. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Cancer Diagnostics Market
Buy Now GET FREE SAMPLE
Companion Diagnostics for Oncology Market
Buy Now GET FREE SAMPLE
Breast Cancer Diagnostics Market
Buy Now GET FREE SAMPLE
Cancer Tumor Profiling Market
Buy Now GET FREE SAMPLE
Clinical Oncology Next Generation Sequencing Market
Buy Now GET FREE SAMPLE
Cancer Biomarkers Market
Buy Now GET FREE SAMPLE
Molecular Diagnostics Market
Buy Now GET FREE SAMPLE
Ovarian Cancer Diagnostic Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Next Generation Cancer Diagnostics Market

Report ID: SQMIG35A2226

$5,300
BUY NOW GET FREE SAMPLE